StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen GAAP R&D Expense as % of Product Sales by Quarter

GAAP R&D Expense as % of Product Sales (%) (%)

QuarterlyAnnual

Amgen GAAP R&D Expense as % of Product Sales: 19.6% in Q2 2026, down 0.3 pts from a year earlier.

Latest, Q2 2026
19.6%
Period ended Jun 30, 2026
Change on a year earlier
-0.3 pts
19.9% in Q2 2025
History
36 quarters
Since Q3 2017
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| GAAP research and development expenses as a percentage of product sales | 19.6 | % | 19.9 | % | 20.2 | % | 19.4 | %”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGAAP R&D Expense as % of Product Sales (%) (%)Year on yearSource
Q2 2026Jun 30, 202619.6%-0.3 ptsForm 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202620.9%+2.0 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202522.9%+3.1 ptsForm 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202520.8%+3.0 ptsForm 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202519.9%+1.9 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 202518.9%0.0 ptsForm 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202419.8%+0.2 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202417.8%+1.3 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202418.0%+1.3 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202418.9%+0.8 ptsForm 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202319.6%-0.6 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202316.5%-1.3 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202316.7%+0.2 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202318.1%+1.4 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202220.2%-1.3 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202217.8%-4.7 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Cite this data

StockData. (2026). Amgen GAAP R&D Expense as % of Product Sales (%), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-rd-pct

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.